Company news

Novavax, Inc. news in 2022

Novavax, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

December 29, 2022

Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock

December 27, 2022

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

December 14, 2022

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

December 14, 2022

Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

December 13, 2022

Novavax Announces Proposed $125 Million Public Offering of Common Stock

December 13, 2022

Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents

December 6, 2022

Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference

December 1, 2022

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

November 28, 2022

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

November 17, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults

November 8, 2022

Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights

November 7, 2022

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

November 7, 2022

Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

October 31, 2022

Novavax Appoints Rick Rodgers to Board of Directors

October 31, 2022

Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022

October 19, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

October 18, 2022

Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains

October 12, 2022

Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

October 11, 2022

Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022

October 9, 2022

Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom

September 26, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

September 15, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older

September 15, 2022

Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older

September 12, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older

September 11, 2022

Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

September 1, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

August 31, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

August 25, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17

August 18, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

August 17, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults

August 16, 2022

Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

August 14, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17

August 11, 2022

Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

August 10, 2022

Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights

August 7, 2022

Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years

August 3, 2022

Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022

July 31, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17

July 25, 2022

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

July 25, 2022

U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older

July 18, 2022

Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes

July 18, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

July 12, 2022

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

July 10, 2022

Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

July 4, 2022

Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants

June 27, 2022

Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over

June 22, 2022

Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

June 22, 2022

Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

June 12, 2022

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

June 6, 2022

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

May 8, 2022

Older news releases →

Calls in 2022

Decks in 2022